Debiopharm and Ipsen Win the 2020 ASAP Alliance Excellence Awards

On June 23th 2020, the ASAP Alliance Excellence Awards, the world’s only awards recognizing advancements in the practice of executing strategic alliances, honored Debiopharm and Ipsen for their long-term partnership for Triptorelin, known under the brand name “Decapeptyl®” in most countries.

The unique characteristics of the Debiopharm/Ipsen alliance are its longevity and performance. Established 35 years ago, the partnership is set to continue over the next 15 years driven by a shared bold ambition. The ongoing alliance brought unprecedented sales growth in 5 therapeutic indications through geographical expansion, innovation in multiple new formulations and delivery devices, and development of new therapeutic indications.

When the time came to renew the contract and define an alliance “reset”, both companies put significant effort to address a number of economic and operational challenges. This revitalized alliance resulted in a partnership with a new economic model, new operating and governance frameworks, including joint development programs and an enhanced collaborative spirit.

This long-standing partnership honor was awarded based on a variety of end result criteria including —exemplary quality, innovative nature, significance of impact, and openness of the alliance. The ASAP also considered the practices, tools, and methodologies instituted in support of successful formation and management.

As Fabrice Paradies, Director of Industrial Business Development and Global Alliances, explained:

The Ipsen-Debiopharm alliance for Decapeptyl exemplifies both the virtues and challenges of alliances. Even when facing difficulty to align our strategic and economic aims, we were able to exemplify the resiliency and agility needed to beat the odds and co-formulate the agreements required to continue our steady progress together.

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). The compound has been engineered to deliver superagonist activity and works by decreasing the amount of certain hormones in the body and is used to treat advanced carcinoma of the prostate gland, Endometriosis, Central Precocious Puberty, breast Cancer and IVF.


news updated 24.06.2020